TITLE

Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria

AUTHOR(S)
Dennis, Brittany B.; Roshanov, Pavel S.; Naji, Leen; Bawor, Monica; Paul, James; Plater, Carolyn; Pare, Guillaume; Worster, Andrew; Varenbut, Michael; Daiter, Jeff; Marsh, David C.; Desai, Dipika; Samaan, Zainab; Thabane, Lehana
PUB. DATE
October 2015
SOURCE
Trials;10/21/2015, Vol. 16 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Background: Eligibility criteria that result in the exclusion of a substantial number of patients from randomized trials jeopardize the generalizability of treatment effect to much of the clinical population. This is important when evaluating opioid substitution and antagonist therapies (OSATs), especially given the challenges associated with treating the opioid-dependent population. We aimed to identify OSAT trials' eligibility criteria, quantify the percentage of the clinical population excluded by these criteria, and determine how OSAT guidelines incorporate evidence from these trials.Methods: We performed a systematic review to identify the eligibility criteria used across trials. We searched Medline, EMBASE, PsycINFO, Web of Science, Cochrane Library, Cochrane Clinical Trials Registry (CTR), World Health Organization International CTR Platform Search Portal, and the National Institutes of Health CTR databases from inception to January 1, 2014. To quantify the effect of trials' eligibility criteria on generalizability, we applied these criteria to data from an observational study of opioid-dependent patients (n = 394). We then accessed the Canadian, American, British, and World Health Organization (WHO) OSAT guidelines to evaluate how evidence is used in the recommendations.Results: Among the 60 trials identified the majority (≥50 % of trials) exclude patients with psychiatric (60 %) and physical comorbidity (51.7 %). Additionally, we found 19 trials exclude patients with current alcohol/substance-use problems (31.7 %), and 29 (48.3 %) exclude patients taking psychotropic medications. These criteria were restrictive and in some cases rendered 70 % of the observational sample ineligible. North American OSAT guidelines made strong recommendations supported by evidence with poor generalizability. National Institute of Health and Care Excellence (NICE) and WHO guidelines for opioid misuse provide a critical assessment of the literature used to inform their recommendations.Conclusions: Trials assessing OSATs often exclude patients with concurrent disorders. If the excluded patients respond differently to treatment, results from these trials are likely to overestimate the true effectiveness of OSATs. North American guidelines should consider these limitations when drafting clinical recommendations.
ACCESSION #
110581443

 

Related Articles

  • Cognitive Functioning in Formerly Opioid-Dependent Adults after At Least 1 Year of Abstinence: A Naturalistic Study. Schmidt, Peggy; Haberthür, Annina; Soyka, Michael; Haberthür, Annina // European Addiction Research;Feb2018, Vol. 23 Issue 6, p269 

    This study is an evaluation of cognitive functioning in formerly opioid-dependent adults after at least 1 year of abstinence. Participants (45 formerly opioid-dependent patients, referred to as abstainers, and 45 matched healthy controls) completed a structured screening and subsequent cognitive...

  • The Epidemic as Stigma: The Bioethics of Opioids. Buchman, Daniel Z.; Leece, Pamela; Orkin, Aaron // Journal of Law, Medicine & Ethics;Winter2017, Vol. 45 Issue 4, p607 

    In this paper, we claim that we can only seek to eradicate the stigma associated with the contemporary opioid overdose epidemic when we understand how opioid stigma and the epidemic have co-evolved. Rather than conceptualizing stigma as a parallel social process alongside the epidemiologically...

  • Defining Substance Use Disorders: Do We Really Need More Than Heavy Use? Rehm, J.; Marmet, S.; Anderson, P.; Gual, A.; Kraus, L.; Nutt, D. J.; Room, R.; Samokhvalov, A. V.; Scafato, E.; Trapencieris, M.; Wiers, R. W.; Gmel, G. // Alcohol & Alcoholism;Nov/Dec2013, Vol. 48 Issue 6, p633 

    Aims: The aim of the study was to explore whether the concept of heavy substance use over time can be used as definition of substance use disorder. Methods: Narrative review. Results: Heavy use over time clearly underlies the neurobiological changes asso-ciated with current thinking of substance...

  • Substance use in women: Current status and future directions. Lal, Rakesh; Deb, Koushik Sinha; Kedia, Swati // Indian Journal of Psychiatry;2015 Supplement2, Vol. 57, pS275 

    Alcohol and substance use, until recently, were believed to be a predominantly male phenomenon. Only in the last few decades, attention has shifted to female drug use and its repercussions in women. As the numbers of female drug users continue to rise, studies attempt to understand...

  • Suboxone® (Buprenorphine/Naloxone) as an Agonist Opioid Treatment in Spain: A Budgetary Impact Analysis. Martínez-Raga, José; Saiz, Francisco González; Pascual, César; Casado, Miguel A.; Torres, Francisco J. Sabater // European Addiction Research;2010, Vol. 16 Issue 1, p31 

    Objective: To evaluate the economic impact of buprenorphine/naloxone (B/N) as an agonist opioid treatment for opiate dependence. Methods: A budgetary impact analysis model was designed to calculate the annual costs (drugs and associated costs) to the Spanish National Healthcare System of...

  • National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Jones, Christopher M.; Campopiano, Melinda; Baldwin, Grant; McCance-Katz, Elinore // American Journal of Public Health;Aug2015, Vol. 105 Issue 8, pe55 

    Objectives. We estimated national and state trends in opioid agonist medication-assisted treatment (OA-MAT) need and capacity to identify gaps and inform policy decisions. Methods. We generated national and state rates of past-year opioid abuse or dependence, maximum potential buprenorphine...

  • Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review. Korthuis, P. Todd; McCarty, Dennis; Weimer, Melissa; Bougatsos, Christina; Blazina, Ian; Zakher, Bernadette; Grusing, Sara; Devine, Beth; Chou, Roger // Annals of Internal Medicine;2/21/2017, Vol. 166 Issue 4, p268 

    Greater integration of medication-assisted treatment (MAT) for opioid use disorder (OUD) in U.S. primary care settings would expand access to treatment for this condition. Models for integrating MAT into primary care vary in structure. This article summarizes findings of a technical report for...

  • Substance abuse treatment staff perceptions of intimate partner victimization among female clients. Kunins, Hillary; Gilbert, Louisa; Whyte-Etere, Antonette; Meissner, Paul; Zachary, Mary // Journal of Psychoactive Drugs;Sep2007, Vol. 39 Issue 3, p251 

    Providing intimate partner violence (IPV)-related services to women enrolled in substance abuse treatment programs has the potential to reach a population disproportionately affected by IPV. Integrating basic IPV services into substance abuse treatment, however, poses challenges to organizations...

  • The Clinical Efficacy of Mindfulness-Based Treatments for Alcohol and Drugs Use Disorders: A Meta-Analytic Review of Randomized and Nonrandomized Controlled Trials. Cavicchioli, Marco; Movalli, Mariagrazia; Maffei, Cesare // European Addiction Research;Jul2018, Vol. 24 Issue 3, p137 

    Introduction: The current study aims to evaluate if and to what extent mindfulness-based interventions (MBIs) could promote an incremental effectiveness compared to interventions usually provided in clinical practice to treat Alcohol and Drugs Use Disorders. In line with this aim,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics